Data as of Sep 29
| -0.02 / -0.72%|
The 2 analysts offering 12-month price forecasts for ZIOPHARM Oncology Inc have a median target of 6.00, with a high estimate of 11.00 and a low estimate of 1.00. The median estimate represents a +118.18% increase from the last price of 2.75.
The current consensus among 3 polled investment analysts is to Buy stock in ZIOPHARM Oncology Inc. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.